Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 11Other hematologic neoplasm 7Classical hematology 2Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Lymphoma, Follicular 200Lymphoma 199Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Leukemia 89Hodgkin Disease 89Lymphoma, Mantle-Cell 80Lymphoma, B-Cell, Marginal Zone 66Burkitt Lymphoma 65Leukemia, Myeloid, Acute 55Multiple Myeloma 52Lymphoma, Large-Cell, Immunoblastic 48Recurrence 44Neoplasms 38Myelodysplastic Syndromes 38Lymphoma, T-Cell, Cutaneous 36Mycosis Fungoides 30Lymphoma, Large-Cell, Anaplastic 30Waldenstrom Macroglobulinemia 28Leukemia, Myeloid, Chronic-Phase 28Myeloproliferative Disorders 27Lymphoma, B-Cell 27Leukemia, Myeloid, Accelerated Phase 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Sezary Syndrome 25Leukemia, Biphenotypic, Acute 25Blast Crisis 24Primary Myelofibrosis 22

Interventions

ponatinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Bone Marrow Diseases × Lymphoid × Clear all
NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡